Myriad Genetics, Inc. News Releases https://investor.myriad.com/ Myriad Genetics, Inc. News Releases en Myriad Genetics to Present Multiple Studies at the 2019 American Society of Clinical Oncology Annual Meeting https://investor.myriad.com/news-releases/news-release-details/myriad-genetics-present-multiple-studies-2019-american-society SALT LAKE CITY, May 14, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in personalized medicine, today announced that it will present results from multiple studies at the 2019 American Society of Clinical Oncology (ASCO) annual meeting to be held May 31 to June 4, 2019 in Tue, 14 May 2019 07:04:49 -0400 Myriad Genetics, Inc. News Releases 20446 New Publication Shows the EndoPredict® Test Identifies Women with Early-Stage Breast Cancer Who Can Forgo Extended Endocrine Therapy https://investor.myriad.com/news-releases/news-release-details/new-publication-shows-endopredictr-test-identifies-women-early New Study Finds Approximately 62 Percent of Women May Not Need Extended Endocrine Therapy Five Years After Diagnosis SALT LAKE CITY, May 09, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a global leader in personalized medicine, today announced that the EndoPredict ® test (EPclin) Thu, 09 May 2019 07:04:48 -0400 Myriad Genetics, Inc. News Releases 20441 Myriad Genetics Reports Fiscal Third-Quarter 2019 Financial Results https://investor.myriad.com/news-releases/news-release-details/myriad-genetics-reports-fiscal-third-quarter-2019-financial Total Third-Quarter Revenues of $216.6 Million, Up 18 Percent Third-Quarter Diluted EPS of $0.09 and Adjusted EPS of $0.46, Up 35 Percent SALT LAKE CITY, May 07, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN, “Myriad” or the “Company”), a global leader in personalized medicine, today Tue, 07 May 2019 16:04:56 -0400 Myriad Genetics, Inc. News Releases 20416 Myriad Announces Coverage Decision by Kroger® Prescription Plans for GeneSight® https://investor.myriad.com/news-releases/news-release-details/myriad-announces-coverage-decision-krogerr-prescription-plans-0 Agreement Also Includes In-store Interventions at Kroger Pharmacies Nationwide SALT LAKE CITY, May 01, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a worldwide leader in personalized medicine, today announced that Kroger Prescription Plans, will provide GeneSight ® as an benefit Wed, 01 May 2019 16:05:16 -0400 Myriad Genetics, Inc. News Releases 20406 Myriad Genetics to Present at Two Upcoming Healthcare Conferences https://investor.myriad.com/news-releases/news-release-details/myriad-genetics-present-two-upcoming-healthcare-conferences-1 SALT LAKE CITY, May 01, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and personalized medicine, announced that it will be presenting at two upcoming healthcare conferences. R. Bryan Riggsbee, chief financial officer, will present at the Bank of Wed, 01 May 2019 07:05:09 -0400 Myriad Genetics, Inc. News Releases 20391 EndoPredict® Predicts the Chemotherapy Benefit in Women with Early ER-positive, HER2-negative Breast Cancer https://investor.myriad.com/news-releases/news-release-details/endopredictr-predicts-chemotherapy-benefit-women-early-er New Study Finds Many Women May Receive Unnecessary Chemotherapy Treatment SALT LAKE CITY, April 30, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a global leader in personalized medicine, today announced an international team of cancer researchers has found that EndoPredict ® test Tue, 30 Apr 2019 11:16:56 -0400 Myriad Genetics, Inc. News Releases 20386 Myriad to Announce Fiscal Third-Quarter 2019 Financial Results on May 7, 2019 https://investor.myriad.com/news-releases/news-release-details/myriad-announce-fiscal-third-quarter-2019-financial-results-may SALT LAKE CITY, April 23, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in personalized medicine, today announced that it will hold its fiscal third-quarter 2019 sales and earnings conference call with investors and analysts at 4:30 p.m. Tue, 23 Apr 2019 16:05:11 -0400 Myriad Genetics, Inc. News Releases 20371 Myriad to Present Multiple Women’s Health Studies at the 2019 American College of Obstetricians and Gynecologists Annual Meeting https://investor.myriad.com/news-releases/news-release-details/myriad-present-multiple-womens-health-studies-2019-american SALT LAKE CITY, April 23, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in personalized medicine, today announced that its Myriad Women’s Health business unit will present data from several studies at the 2019 Annual Clinical and Scientific meeting of The American College Tue, 23 Apr 2019 07:05:10 -0400 Myriad Genetics, Inc. News Releases 20366 Myriad Genetics Named to Forbes 2019 List of America's Best Midsize Employers and the Women Tech Council’s 2019 Shatter List https://investor.myriad.com/news-releases/news-release-details/myriad-genetics-named-forbes-2019-list-americas-best-midsize Creating a Culture of Diversity, Inclusion and Opportunity Is a Top Company Priority SALT LAKE CITY, April 17, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a global leader in personalized medicine, today announced today announced that the company was named to Forbes 2019 list Wed, 17 Apr 2019 07:05:09 -0400 Myriad Genetics, Inc. News Releases 20361 Myriad Genetics Submits First Module of the Premarket Approval Application to FDA for the myChoice® HRD CDx Test https://investor.myriad.com/news-releases/news-release-details/myriad-genetics-submits-first-module-premarket-approval myChoice HRD Is Intended to Identify Patients with Ovarian, Fallopian or Primary Peritoneal Cancer Who May Benefit from Treatment with Zejula SALT LAKE CITY, April 09, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in personalized medicine, today announced that it has Tue, 09 Apr 2019 07:05:10 -0400 Myriad Genetics, Inc. News Releases 20356